HSV vectors for gene therapy of chronic pain

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 5, 2008, Pages 449-455

  Srinivasan, R ^a   Fink, D J ^b   Glorioso, J C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chronic pain; Endomorphin; Enkephalin; GAD67; GDNF; HSV; IL 4

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ENDORPHIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CYTOKINE; ENDOMORPHIN 2; ETANERCEPT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 67; HERPESVIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 4; MORPHINE; MU OPIATE RECEPTOR; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PROENKEPHALIN; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ALLERGIC ENCEPHALOMYELITIS; ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTISENSE THERAPY; BLADDER IRRITATION; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CYTOKINE PRODUCTION; DNA REPLICATION; DORSAL ROOT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; EXPERIMENTAL MODEL; FACE PAIN; GENE EXPRESSION; HUMAN CYTOMEGALOVIRUS; HYPERALGESIA; IMMEDIATE EARLY GENE; NERVOUS SYSTEM; NEUROIMMUNOLOGY; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; POLYARTHRITIS; PROMOTER REGION; QUALITY OF LIFE; REVIEW; TRANSGENE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANALGESIA; ANALGESICS; CHRONIC DISEASE; GANGLIA, SPINAL; GENE THERAPY; GENETIC VECTORS; HUMANS; PAIN; SIMPLEXVIRUS; SOMATOFORM DISORDERS; SPINE; TRANSDUCTION, GENETIC;

ANIMALIA; SIMPLEXVIRUS;

EID: 53249097532     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Niv D, Devor M: Chronic pain as a disease in its own right. Pain Pract (2004) 4(3):179-181.
2. Woolf CJ, Salter MW: Neuronal plasticity: Increasing the gain in pain. Science (2000) 288(5472):1765-1769.
3. DeLeo JA: Basic science of pain. J Bone Joint Surg Am (2006) 88(Suppl 2):58-62.
4. Munir MA, Enany N, Zhang JM: Nonopioid analgesics. Med Clin North Am (2007) 91(1):97-111.
5. 2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci (2004) 25(9):465-470.
6. Przewlocki R, Przewlocka B: Opioids in chronic pain. Eur J Pharmacol (2001) 429(1-3):79-91.
7. Ballantyne JC, Shin NS: Efficacy of opioids for chronic pain: A review of the evidence. Clin J Pain (2008) 24(6):469-478.
8. v1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci (2008) 28(26):6652-6658.
9. Kim J, Yoon YS, Lee H, Chang JW: AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. Acta Neurochir Suppl (2008) 101:99-105.
10. Hao S, Mata M, Glorioso JC, Fink DJ: Gene transfer to interfere with TNF? signaling in neuropathic pain. Gene Ther (2007) 14(13):1010-1016. • This study demonstrated the presence of a novel reverse signaling through glial mTNFα.
11. Tzabazis AZ, Pirc G, Votta-Velis E, Wilson SP, Laurito CE, Yeomans DC: Antihyperalgesic effect of a recombinant herpes virus encoding antisense for calcitonin gene-related peptide. Anesthesiology (2007) 106(6):1196-1203.
12. Ganju P, Hall J: Potential applications of siRNA for pain therapy. Expert Opin Biol Ther (2004) 4(4):531-542.
13. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J: siRNA relieves chronic neuropathic pain. Nucleic Acids Res (2004) 32(5):e49.
14. Kang W, Wilson MA, Bender MA, Glorioso JC, Wilson SP: Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive. Brain Res (1998) 792(1):133-135.
15. Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PT: Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex. Nature (2003) 424(6946):316-320.
16. Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M: Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther (2002) 9(20):1387-1395.
17. Xu Y, Gu Y, Xu GY, Wu P, Li GW, Huang LY: Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: A strategy to increase opioid antinociception. Proc Natl Acad Sci USA (2003) 100(10):6204-6209. • The first demonstration of opiate receptor gene transfer and an external analgesic agent to treat pain.
18. Finegold AA, Mannes AJ, Iadarola MJ: A paracrine paradigm for in vivo gene therapy in the central nervous system: Treatment of chronic pain. Hum Gene Ther (1999) 10(7):1251-1257.
19. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL: Cytokine involvement in dynorphin-induced allodynia. Pain (2000) 84(2-3):159-167.
20. Yu CG, Fairbanks CA, Wilcox GL, Yezierski RP: Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. J Pain (2003) 4(3):129-140.
21. Storek B, Reinhardt M, Wang C, Janssen WG, Harder NM, Banck MS, Morrison JH, Beutler AS: Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci USA (2008) 105(3):1055-1060.
22. Wu Z, Asokan A, Samulski RJ: Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther (2006) 14(3):316-327.
23. Jacobs A, Breakefield XO, Fraefel C: HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part I. HSV-1 structure, replication and pathogenesis. Neoplasia (1999) 1(5):387-401.
24. Hill JM, Ball MJ, Neumann DM, Azcuy AM, Bhattacharjee PS, Bouhanik S, Clement C, Lukiw WJ, Foster TP, Kumar M, Kaufman HE, Thompson HW: The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender. J Virol (2008) 82(16):8230-8234.
25. Goins WF, Wolfe D, Krisky DM, Bai Q, Burton EA, Fink DJ, Glorioso JC: Delivery using herpes simplex virus: An overview. Methods Mol Biol (2004) 246:257-299.
26. Burton EA, Wechuck JB, Wendell SK, Goins WF, Fink DJ, Glorioso JC: Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells (2001) 19(5):358-377.
27. DeLuca NA, McCarthy AM, Schaffer PA: Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol (1985) 56(2):558-570.
28. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB, Watkins SC, Glorioso JC: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther (1998) 5(11):1517-1530.
29. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 5(12):1593-1603.
30. Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC: Engineering herpes simplex virus vectors for CNS applications. Exp Neurol (1999) 159(1):34-46.
31. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC: Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA (1999) 96(6):3211-3216.
32. Antunes Bras JM, Epstein AL, Bourgoin S, Hamon M, Cesselin F, Pohl M: Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem (1998) 70(3):1299-1303.
33. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ: Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther (2001) 8(7):551-556.
34. Braz J, Beaufour C, Coutaux A, Epstein AL, Cesselin F, Hamon M, Pohl M: Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci (2001) 21(20):7881-7888.
35. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ: Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain (2003) 102(1-2):135-142. •• The first combined use of gene therapy and systemically administered drugs that demonstrated an enhanced therapeutic efficacy without the development of tolerance to gene therapy.
36. Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, Hu X, Glorioso JC, Fink DJ: Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol (2002) 52(5):662-665. • This study provided preclinical data for the first clinical trial to treat cancer pain with enkephalin gene therapy.
37. Yoshimura N, Franks ME, Sasaki K, Goins WF, Goss J, Yokoyama T, Fraser MO, Seki S, Fink J, Glorioso J, de Groat WC et al: Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology (2001) 57(6 Suppl 1):116.
38. Meunier A, Latrémolière A, Mauborgne A, Bourgoin S, Kayser V, Cesselin F, Hamon M, Pohl M: Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther (2005) 11(4):608-616.
39. Lu Y, McNearney TA, Lin W, Wilson SP, Yeomans DC, Westlund KN: Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol Ther (2007) 15(10):1812-1819.
40. Yeomans DC, Lu Y, Laurito CE, Peters MC, Vota-Vellis G, Wilson SP, Pappas GD: Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol Ther (2006) 13(3):589-597. • The first use of enkephalin gene therapy to treat pain in non-human primates.
41. Reichling DB, Basbaum AI: Contribution of brainstem GABAergic circuitry to descending antinociceptive controls: II. Electron microscopic immunocytochemical evidence of GABAergic control over the projection from the periaqueductal gray to the nucleus raphe magnus in the rat. J Comp Neurol (1990) 302(2):378-393.
42. Liu J, Wolfe D, Hao S, Huang S, Glorioso JC, Mata M, Fink DJ: Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther (2004) 10(1):57-66. • The first demonstration that HSV GAD67 gene therapy was effective in the treatment of spinal cord injury pain.
43. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ: Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol (2005) 57(6):914-918.
44. Zadina JE: Isolation and distribution of endomorphins in the central nervous system. Jpn J Pharmacol (2002) 89(3):203-208.
45. Soignier RD, Vaccarino AL, Brennan AM, Kastin AJ, Zadina JE: Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice. Life Sci (2000) 67(8):907-912.
46. Wolfe D, Hao S, Hu J, Srinivasan R, Goss J, Mata M, Fink DJ, Glorioso JC: Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain (2007) 133(1-3):29-38. •• The first description of a recombinant endomorphin gene and its ability to control neuropathic pain.
47. Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB: Potent analgesic effects of GDNF in neuropathic pain states. Science (2000) 290(5489):124-127.
48. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ: HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther (2003) 8(3):367-375.
49. DeLeo JA, Yezierski RP: The role of neuroinflammation and neuroimmune activation in persistent pain. Pain (2001) 90(1-2):1-6.
50. Watkins LR, Milligan ED, Maier SF: Spinal cord glia: New players in pain. Pain (2001) 93(3):201-205.
51. DeLeo JA, Tanga FY, Tawfik VL: Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/ hyperalgesia. Neuroscientist (2004) 10(1):40-52.
52. Wieseler-Frank J, Maier SF, Watkins LR: Glial activation and pathological pain. Neurochem Int (2004) 45(2-3):389-395.
53. Ohtori S, Takahashi K, Moriya H, Myers RR: TNF-α and TNF-α receptor type 1 upregulation in glia and neurons after peripheral nerve injury: Studies in murine DRG and spinal cord. Spine (2004) 29(10):1082-1088.
54. Barnes PJ, Karin M: Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med (1997) 336(15):1066-1071.
55. Onda A, Yabuki S, Kikuchi S: Effects of neutralizing antibodies to tumor necrosis factor-α on nucleus pulposus-induced abnormal nociresponses in rat dorsal horn neurons. Spine (2003) 28(10):967-972.
56. Sommer C, Schmidt C, George A: Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol (1998) 151(1):138-142.
57. Schäfers M, Svensson CI, Sommer C, Sorkin LS: Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci (2003) 23(7):2517-2521.
58. Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS: Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett (2005) 379(3):209-213.
59. Peng XM, Zhou ZG, Glorioso JC, Fink DJ, Mata M: Tumor necrosis factor-α contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol (2006) 59(5):843-851.
60. te Velde AA, Huijbens RJ, Heije K, de Vries JE, Figdor CG: Interleukin-4 (IL-4) inhibits secretion of IL-1 β, tumor necrosis factor α, and IL-6 by human monocytes. Blood (1990) 76(7):1392-1397.
61. Mijatovic T, Kruys V, Caput D, Defrance P, Huez G: Interleukin-4 and -13 inhibit tumor necrosis factor-α mRNA translational activation in lipopolysaccharide-induced mouse macrophages. J Biol Chem (1997) 272(22):14394-14398.
62. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L, Glorioso JC, Comi G, Martino G: Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther (2001) 8(1):13-19.
63. Poliani PL, Brok H, Furlan R, Ruffini F, Bergami A, Desina G, Marconi PC, Rovaris M, Uccelli A, Glorioso JC, Penna G et al: Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther (2001) 12(8):905-920.
64. Hao S, Mata M, Glorioso JC, Fink DJ: HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain (2006) 2:6. • The first demonstration that HSV-expressed IL-4 could be used to treat chronic pain.
65. Wood JN, Boorman JP, Okuse K, Baker MD: Voltage-gated sodium channels and pain pathways. J Neurobiol (2004) 61(1):55-71.
66. Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature (2001) 413(6852):203-210.
67. v1.7 sodium channels in primary afferents. Hum Gene Ther (2005) 16(2):271-277.
68. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther (1999) 10(14):2325-2335.
69. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 11(17):2389-2401.
70. Diamyd Medical AB: Diamyd strengthens financial position and executes a fully subscribed direct placement. Press Release (2008): April 21.
71. Wilson SP, Yeomans DC: Virally mediated delivery of enkephalin and other neuropeptide transgenes in experimental pain models. Ann NY Acad Sci (2002) 971:515-521.